Addressing the supply chain problems in the healthcare industry

Biospectrumindia | May 13, 2019

Recent is the time when the wave of health consciousness and awareness took place and catalyzed the healthcare industry to pull up the socks. The rise in income level, high risks of lifestyle diseases and easy accessibility of the life insurance plans have also made it a whole lot simpler for people to opt for regular health checkups and diagnostics, leading to the strong demands for affordable healthcare facilities all across the nation. With projects as influential as Ayushman Bharat and heavy capital investments in diagnostics and pharmaceutical sectors made in 2018, the growth of the healthcare industry is projected to reach $280 billion by the end of 2020.  Looking at the performance of the industry and the attractive and tremendous opportunities for both public and private healthcare delivery systems, India is all set to become the biggest hub for world-class healthcare services. However, they are largely dominated by some of the challenges, which might appear trivial at prima facie but are major roadblocks.

Spotlight

Managing the complex financial aspects of your healthcare business is a daunting task. You need a holistic, intuitive and intelligent solution that empowers you to be proactive and control costs with precision. Use this guide to make the most informed decision when selecting an ERP solution where better patient care is the bottom line.


Other News
FUTURE OF HEALTHCARE

Virtua Health and Medtronic Share Plans to Reimagine Traditional Health Care Models

Virtua Health | December 16, 2021

Virtua Health and Medtronic plc announce a five-year partnership focused on improving delivery of quality care for residents of South Jersey, particularly those who reside in underserved communities or face systemic barriers to care. Medtronic LABS, an independent impact-focused organization funded by Medtronic plc, will simultaneously launch a separate pilot collaboration with the Cherry Hill Free Clinic and Virtua to address care and food access for people with chronic conditions – the first U.S.-based initiative for Medtronic LABS. "I truly believe technology is the path forward to improving human welfare," said Geoff Martha, Chairman and CEO of Medtronic. "This new partnership and collaboration demonstrate the opportunity to use technology to tackle health challenges in a localized, grassroots way. By taking a data-informed approach, we can help improve access and outcomes for patients with chronic conditions in southern New Jersey." "This partnership presents a significant opportunity to accelerate health equity and better outcomes for individuals and families in our community. Together, we will apply the latest research and innovation to the fundamentals of community-based care, allowing us to identify and empower those who need support to achieve the best-possible quality of life." Dennis W. Pullin, FACHE, president and CEO of Virtua Health The scope of the partnership includes the following projects and will expand over time. Heart Health: Medtronic plc and Virtua Health will develop a program to optimize care for hospital patients diagnosed with heart failure, with a focus on slowing the progression of the disease and enhancing the experience of both patient and provider. By employing Medtronic's data-driven, decision-support tools, Virtua clinicians will provide ongoing resources post-hospitalization, minimizing the likelihood of readmission and creating sustainable, enriching solutions for the individual. Outpatient Care Continuity: The partnership will also optimize patient care in high-value outpatient settings, including ambulatory surgery centers. Additionally, Medtronic plc and Virtua will expand Virtua's hospital at home program, which is due to launch officially in early 2022 and aims to reduce the resource-strain on the health system while allowing eligible patients to heal from the comfort of home. Medtronic LABS' collaboration intends to address population health in the following ways: Community Health and the Cherry Hill Free Clinic: Community health workers and clinicians at the Cherry Hill Free Clinic will utilize Medtronic LABS' digital health platform, extending their reach through mobile tools and point-of-care diagnostics. Those identified as having (or being at risk for) chronic illnesses, such as Type 2 diabetes or hypertension, will then connect to the Cherry Hill Free Clinic for follow-up care. Over time, the platform will become more sophisticated and specific as the data accumulates and reveals localized trends and challenges. Food Access: Medtronic LABS will also support Virtua's Eat Well food access programs, specifically the Food Farmacies located inside Virtua Mount Holly Hospital and the Virtua Health & Wellness Center – Camden. Medtronic LABS and Virtua will identify those at risk for food insecurity – due to financial circumstances or limited health literacy – and connect them to free food, nutrition education, and social-work services. "I am honored that Medtronic LABS and Virtua recognize the essential services we provide at the Cherry Hill Free Clinic, and that they are combining their resources and expertise toward enhancing continuity of care for existing and prospective patients," said Jubril Oyeyemi, MD, founder and chief medical officer of the Cherry Hill Free Clinic. "The CDC estimates that 20 percent of Camden County residents do not have health insurance. By creating pathways to care, we build healthier communities." "Medtronic LABS has trained more than 2,000 health workers and provided screenings to more than a million people worldwide. To date, we have focused our efforts on communities in Kenya, Ghana, India, and the Philippines, which is why we are thrilled to partner with Virtua Health on our first U.S.-based endeavor," said Ruchika Singhal, vice president of Medtronic LABS. "In time, this collaboration will create scalable, replicable improvements to the care-delivery model while advancing health and wellness on an individual level." About the Partners Medtronic: Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. Medtronic LABS is an independent, non-profit structure with multiple entities including an operating foundation, a social business, an in-country non-profit, and for-profit subsidiaries. Medtronic LABS is setting out to design the health system of the future: one that is equitable, tech-enabled, and patient-centered. To date, Medtronic LABS has screened more than 1M patients and improved clinical outcomes for over 35K patients in Kenya, Ghana, India, and the Philippines. Virtua Health is an integrated health care system and the trusted partner for personalized health care and wellness for communities in southern New Jersey. With more than 280 locations and 14,000 colleagues, Virtua provides high-quality care with more than two million annual encounters across the full range of community and tertiary health services – from preventive care to urgent care through specialty services in cancer, women's health, neuroscience, and orthopedics to complex minimally invasive cardiac surgery and organ transplantation. Performing more than 175,000 surgeries at its hospitals and network of ambulatory centers, Virtua is one of the largest providers of surgery in the state. As a not-for-profit leader, Virtua continues to improve social determinants in health and has distributed more than 160,000 pounds of fresh produce in underserved areas to address food insecurity. Virtua is advancing important partnerships into the future to help you be well, get well, and stay well. Cherry Hill Free Clinic (CHFC) is an independent 501(c)(3) with the mission of providing free primary care to the uninsured and under-insured. CHFC is supported by Virtua Health, which provides lab, radiology and, in some cases, specialty care to CHFC patients.

Read More

FUTURE OF HEALTHCARE

Althea Expands Its Growing Broadband Coverage Area to Tacoma WA

Althea | March 26, 2022

Althea is proud to announce Tacoma, WA is the latest addition to its growing broadband coverage area, with installations and infrastructure investment focused in the Hilltop neighborhood. Founded in 2017, Althea’s mission is rooted in the belief that affordable broadband connectivity is a fundamental right for all people that strengthens communities, economic growth, educational opportunities, and healthcare access. Althea is a distributed Internet Service Provider which works together with local communities and network operators to provide sustainable high speed and low cost broadband access. This is made possible by Althea’s unique technology, infrastructure, and routing protocol. Althea’s routing protocol allows the service and accounting layers of the ISP to be almost entirely automated, and maximizes bandwidth utilization (i.e. delivers lower latency and higher speeds than one would typically experience from a given network connection, when compared to a traditional ISP routing protocol). This technology negates the need for contracts, late fees, and other drawbacks of traditional internet delivery. The mesh topology used to connect users also allows individuals to host infrastructure themselves, growing the network, and earning revenue share for doing so. This keeps value in the community, encourages community involvement, maintains low costs, and creates an ever more resilient network architecture. Althea uses a unique pay-as-you-go payment model, making it easy for users to manage costs. Additionally, each user has access to the always-on free tier, guaranteeing they will have access to no-cost basic internet, regardless of their financial situation. Unlike traditional ISPs, Althea’s technology does not artificially throttle bandwidth or utilize speed tiers either, so users always get the maximum speed their equipment is capable of delivering. Althea users in Tacoma can expect speeds around 100 Mbps and pay, on average, around $25/month. “Many people don’t have access to the internet, not because of availability, but costs and other barriers keep them from this vital resource.We believe internet access is a human right, which is why we provide an always-on, free tier of internet.” Deborah Simpier, Althea CEO and co-founder Hilltop, Tacoma was also one of the first proof-of-concept networks for Althea, partnering in 2020 with Tacoma Cooperative Network and the University of Washington to build and test community led LTE networks. Through this work in Open5GS, Althea developed KeyLTE, which is an embedded EPC inside an Althea home router, which provides flexibility to build and grow LTE/5G networks anywhere, quickly and affordably.

Read More

FUTURE OF HEALTHCARE

Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products

Endonovo Therapeutics, Inc. | April 26, 2022

Endonovo Therapeutics, Inc. announced an agreement with NAMSA – a leading Global Contract Research Organization and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF product SofPulse®. “Engaging NAMSA as strategy advisors to develop and apply proven medical device reimbursement strategies is a huge advantage for Endonovo and our shareholders, according to Endonovo CEO Alan Collier. “NAMSA is a proven medical device development partner with relevant therapeutic know-how that is critical when seeking acceleration of reimbursement efforts and commercialization objectives,” he pointed out. NAMSA was founded in 1967 as a scientific research company and later transitioned into a Global CRO and Medtech (Medical Technologies) reimbursement specialist. Today, it has 1,000 strategic associates who provide Medtech reimbursement advisory expertise to more than 300 clients in 15 global regions. NAMSA offers a full continuum of reimbursement services for medical technologies. Their reimbursement consultants provide: payer relations, medical policy research, coverage advocacy, Healthcare Common Procedure Coding System Current Procedural Terminology code analysis/applications and health economic analysis. “Our team strives to bring impactful products like the Endonovo SofPulse into higher adoption. With this technology, and its favorable economics, there are multiple opportunities ahead for serving populations in need. We will work together with the Endonovo team to improve market access for this novel device in the very near term.”, Joseph Sierra, Director, Reimbursement Consulting, North America, NAMSA NAMSA provides strategic guidance and tactical support to fast-track medical device commercialization and to make an immediate impact on patient healthcare worldwide. NAMSA’s services have grown to include regulatory, reimbursement and quality consulting as well as clinical research. These additions have helped NAMSA to become the pre-eminent 100% medical device-focused Global CRO that offers proven strategic solutions throughout the full development continuum. NAMSA is the only US FDA ASCA accredited medical device biocompatibility laboratory in the world. This allows medical device sponsors to fast-track commercialization efforts, while achieving time and cost efficiencies in every major market of the world. Collier stated: “We are fortunate to be working directly with Joseph Sierra, at NAMSA. With over 10 years of reimbursement experience, and his proven track-record in developing successful medical device reimbursement strategies is exemplary and will be helpful in developing the path toward reimbursement for our main product SofPulse®. Joseph is an adjunct instructor at USC Masters of Health Administration Program, and his prior professional work includes successful stints with NeoFect USA and Medtronic Ltd. where he demonstrated a record of success leading roles in reimbursement programs, analysis, and strategies for their medical devices.” NAMSA’s reimbursement expertise and track-record in the introduction and adoption of medical devices into multiple medical specialties includes: orthopedics, cardiovascular surgery, general surgery, plastic surgery, neurology, robotic surgery and wound care. Collaborating with NAMSA on global reimbursement allows Endonovo to explore reimbursement for the U.S. medical markets as well as the European Union market adoption through SofPulse® medical CE Mark. Additional target markets would be Taiwan and other Asian countries. About Endonovo Therapeutics Inc. Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system disorders, including traumatic brain injury, acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema. It also has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease, non-alcoholic steatohepatitis cardiovascular and peripheral artery disease and ischemic stroke. The Company's noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Read More

MEDICAL DEVICES

Adaptiiv collaborates with HP and Varian to enhance personalization in radiation oncology with 3D printed medical devices

Adaptiiv Medical Technologies Inc. | May 09, 2022

Adaptiiv Medical Technologies Inc. is collaborating with HP Inc. and Varian, a Siemens Healthineers company to advance the quality of and access to personalized cancer care for U.S. patients with 3D printed medical devices. HP's Multi Jet Fusion platform provides access to leading 3D printing technology that is used to produce high-quality, flexible, patient-specific parts at high throughput. HP 3D printing is suitable for use in healthcare because of the speed, quality, and economic advantages gained through HP's scalable manufacturing processes. "The combined technology scale of HP and Varian, along with the leading-edge personalization workflow of Adaptiiv, provides the improved solution that clinicians and patients deserve," said Louis Kim, Vice President, 3D Printing at HP. HP is proud to be a part of this collaboration to help advance the treatment of cancers worldwide." Adaptiiv will also work with Varian to expand access to personalized, patient-specific 3D printed medical devices. For more than 70 years, Varian has developed, built, and delivered innovative cancer care technologies and solutions for clinical partners around the globe to help them treat millions of patients each year. This agreement advances Varian's commitment to meeting evolving customer needs and improving the patient experience. "We are energized by Adaptiiv's innovation and this opportunity with HP to further expand our cancer care ecosystem. Addressing our customers' needs is our top priority, and we are confident that this commercial commitment will help us do just that by advancing interoperability with Adaptiiv's 3D printed medical devices for external beam radiation therapy," Ben Moga, Director, Strategic Alliances and Synergy Investments at Varian Earlier this year, Adaptiiv received U.S. FDA 510(k) clearance for the Adaptiiv On Demand service to manufacture and deliver 3D printed patient-specific medical devices. 3D printed medical devices conform to patient anatomy thereby improving the accuracy of dose delivery while the integration of Adaptiiv software into clinical workflows provides improved efficiencies, such as reducing patient set up time both in CT simulation and on the treatment unit. "This is a tremendous milestone for Adaptiiv's vision to democratize personalization in radiation treatment," said Adaptiiv CEO, Alex Dunphy. "Collaborating with brands like HP and Varian who stand for quality and innovation will ensure our solutions reach patients around the world. The last mile of radiation therapy needs to evolve and our solutions provide greater access to personalized care, while improving treatment and creating workflow efficiencies for cancer centres around the world." About Adaptiiv Adaptiiv Medical Technologies Inc. has a software platform that works in conjunction with 3D printing to create medical devices for use in radiation oncology. Adaptiiv is shaping the future of personalized healthcare through innovation and collaboration with industry leaders throughout the world.

Read More

Spotlight

Managing the complex financial aspects of your healthcare business is a daunting task. You need a holistic, intuitive and intelligent solution that empowers you to be proactive and control costs with precision. Use this guide to make the most informed decision when selecting an ERP solution where better patient care is the bottom line.

Resources